Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma.

ABSTRACT: Background/Objectives: Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and poor prognosis, largely owing to its heterogeneity and the involvement of multiple intracellular signaling pathways that contribute to drug resistance. While recent advancements in targeted drug combination therapies, such as dabrafenib and trametinib, show promise for certain GBM subgroups, identifying effective drug combinations across the broader GBM population remains a challenge. Integrin-mediated signaling, particularly through Focal Adhesion Kinase (FAK), plays a pivotal role in GBM pathogenesis and invasion, making it a potential therapeutic target and component of future drug combination strategies. Methods: In this study, we utilized a chemogenomic screening app

SUBMITTER: Furqan M 

PROVIDER: S-EPMC12114623 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature